This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in participants with HFrEF/HFmrEF. A screening period of up to 29 days will be used to assess participants' eligibility. Participants will be randomized into one of two cohorts based on background therapy. Participants will be randomized in a 2:1 ratio (Cohort 1) or 3:1 ratio (Cohort 2). In Cohort 1, participants will receive a single dose of either subcutaneous (s.c.) XXB750 or placebo. In Cohort 2, participants will receive three doses of either s.c. XXB750 or placebo.
This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in HFrEF/HFmrEF.